Literature DB >> 15698634

6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.

Takashi Kondoh1, Makoto Bannai, Hitoo Nishino, Kunio Torii.   

Abstract

Injection with 6-hydroxydopamine (6-OHDA) into the nigrostriatal pathway results in loss of nigrostriatal dopaminergic neurons, which has been used widely as an animal model of Parkinson's disease. In the present study, location and extent of lesions 1 day after 6-OHDA injections (2, 4, 8, or 16 microg as a free base) in the substantia nigra (SN) were evaluated in rats by T(2)-weighted magnetic resonance imaging (MRI). The changes in MRI were also compared to immunohistochemical and behavioral changes. Hyperintense area in MRI was found at the region corresponding to 6-OHDA injection in a dose-dependent manner and was accompanied by a loss of tyrosine hydroxylase (TH)-positive cells. The shape of hyperintense area in the SN appeared to be composed of two components (i.e., circular and longitudinal regions). Administration of a larger dose of 6-OHDA (8-16 microg) was accompanied by an increase in hyperintense area and loss of TH-positive cells beyond the SN. The hyperintense area was observed on the first and third days after 6-OHDA injection, but the size and intensity declined to near normal levels on the ninth day. Rotational behavior induced by methamphetamine reached maximal levels at 4 microg 6-OHDA, and the behavior was maintained with doses up to 16 microg of 6-OHDA. Intrastriatal injection with 6-OHDA was less effective. These results suggest that MRI provides highly valuable information for verifying the size and location of intended lesions as well as for determining the optimal dose of neurotoxins in individual animals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698634     DOI: 10.1016/j.expneurol.2004.12.016

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  11 in total

1.  Dopamine is produced in the rat spinal cord and regulates micturition reflex after spinal cord injury.

Authors:  Shaoping Hou; David M Carson; Di Wu; Michelle C Klaw; John D Houlé; Veronica J Tom
Journal:  Exp Neurol       Date:  2015-12-02       Impact factor: 5.330

Review 2.  Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease.

Authors:  Katherine E Olson; Aditya N Bade; Charles R Schutt; Jingdong Dong; Scott J Shandler; Michael D Boska; R Lee Mosley; Howard E Gendelman; Yutong Liu
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

3.  Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle.

Authors:  Anete Curte Ferraz; Francesca Matheussi; Raphael Escorsim Szawka; Vanessa Rizelio; Ana Márcia Delattre; Paula Rigon; Erica do Espírito Santo Hermel; Léder Leal Xavier; Matilde Achaval; Janete A Anselmo-Franci
Journal:  Neurochem Res       Date:  2008-02-09       Impact factor: 3.996

4.  Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned with microSPECT and quantitative MRI.

Authors:  Nadja Van Camp; Ruth Vreys; Koen Van Laere; Erwin Lauwers; Dirk Beque; Marleen Verhoye; Cindy Casteels; Alfons Verbruggen; Zeger Debyser; Luc Mortelmans; Jan Sijbers; Johan Nuyts; Veerle Baekelandt; Annemie Van der Linden
Journal:  MAGMA       Date:  2010-02-19       Impact factor: 2.310

5.  Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.

Authors:  Anthony C Vernon; William R Crum; Saga M Johansson; Michel Modo
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

6.  Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease.

Authors:  Ana Virel; Erik Faergemann; Greger Orädd; Ingrid Strömberg
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

7.  Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.

Authors:  Michel Modo; William R Crum; Madeline Gerwig; Anthony C Vernon; Priya Patel; Michael J Jackson; Sarah Rose; Peter Jenner; Mahmoud M Iravani
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

8.  Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.

Authors:  Lan-Xiang Liu; Dan Du; Tao Zheng; Yuan Fang; Yan-Sheng Chen; Hui-Ling Yi; Qing-Yuan He; Da-Wei Gao; Qing-Lei Shi
Journal:  Neural Regen Res       Date:  2017-09       Impact factor: 5.135

9.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

10.  Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.

Authors:  Cyril Monnot; Xiaoqun Zhang; Sahar Nikkhou-Aski; Peter Damberg; Per Svenningsson
Journal:  Exp Neurol       Date:  2017-02-20       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.